Table 1 Background of clients who received GT
From: The impact of public insurance on RRSO for HBOC in Japan: a nationwide data study
| Â | short-Pre | Post | P |
|---|---|---|---|
N | 641 | 913 | Â |
BRCA1+/BRCA2+ | 323(50.4%)/318(49.6%) | 416(45.6%)/497(54.4%) | 0.07 |
Average age at GT (SD) | 49.4 (13.0) | 50.0 (12.6) | 0.39 |
Age group | |||
 <40 | 138 | 162 | 0.09 |
 40–45 | 92 | 165 |  |
 45–50 | 135 | 179 |  |
 51< | 276 | 407 |  |
At the time of GT | |||
 History of breast cancer | 463 (72.2%) | 691 (75.7%) | 0.14 |
 History of ovarian cancer | 154 (24.0%) | 197 (21.6%) | 0.28 |
 History of pancreatic cancer | 1 (0.16%) | 2 (0.22%) | – |
Purpose for GT (multiple choice) | |||
 Health care of the individual | 322 (50.2%) | 635 (69.6%) | p < 0.01 |
 For the family | 176 (27.5%) | 279 (30.6%) | p = 0.21 |
 Surgical decision | 52 (8.1%) | 158 (17.3%) | p < 0.01 |
 Chemotherapy options | 239 (37.3%) | 214 (23.4%) | p < 0.01 |
 Research | 48 (7.5%) | 6 (0.7%) | p < 0.01 |
